{
    "title": "113_hr5874",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as ``Tim Fagan's Law'' or the ``Counterfeit \nDrug Enforcement Act of 2014''.\n\nSEC. 2. SALE OR TRADE OF PRESCRIPTION DRUGS KNOWINGLY CAUSED TO BE \n              ADULTERATED OR MISBRANDED; MISREPRESENTATION AS APPROVED \n              DRUGS.\n\n    (a) Criminal Penalty.--Section 303(a) of the Federal Food, Drug, \nand Cosmetic Act (21 U.S.C. 333(a)) is amended by adding at the end the \nfollowing paragraphs:\n    ``(3) Notwithstanding paragraph (1) or (2), in the case of a person \nwho violates subsection (a), (b), or (c) of section 301 with respect to \na drug that is subject to section 503(b)(1)(B), if the person knowingly \ncaused the drug to be adulterated or misbranded and sells or trades the \ndrug, or the person purchases or trades for the drug knowing or having \nreason to know that the drug was knowingly caused to be adulterated or \nmisbranded, the person shall be fined in accordance with title 18, \nUnited States Code, or imprisoned for any term of years or for life, or \nboth.\n    ``(4) Notwithstanding paragraph (1) or (2), in the case of a person \nwho violates section 301(d) with respect to a drug, if the person \ncaused the drug to be misrepresented as a drug that is subject to \nsection 503(b)(1)(B) and for which an approved application is in effect \nunder section 505 and the person sells or trades the drug, or the \nperson purchases or trades for the drug knowing or having reason to \nknow that the drug was knowingly caused to be so misrepresented, the \nperson shall be fined in accordance with title 18, United States Code, \nor imprisoned for any term of years or for life, or both.''.\n    (b) Notification of Food and Drug Administration by \nManufacturers.--Section 505(k) of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 355(k)) is amended by adding at the end the following \nparagraph:\n    ``(6) A manufacturer of a drug that receives or otherwise becomes \naware of information that reasonably suggests that a violation \ndescribed in paragraph (3) or (4) of section 303(a) may have occurred \nwith respect to the drug shall report such information to the Secretary \nnot later than 48 hours after first receiving or otherwise becoming \naware of the information.''.\n\nSEC. 3. USE OF TECHNOLOGIES FOR PREVENTING COUNTERFEITING OF DRUGS.\n\n    Section 502 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n352) is amended by adding at the end the following:\n    ``(dd) If it is a drug and it is not manufactured in accordance \nwith any regulations of the Secretary requiring the use of technologies \nthat the Secretary has determined are technically feasible and will \nassist in preventing violations of this Act to which paragraphs (3) and \n(4) of section 303(a) apply (relating to the knowing adulteration or \nmisbranding of drugs and the knowing misrepresentation of drugs).''.\n\nSEC. 4. COUNTERFEIT DRUGS; INCREASED FUNDING FOR INSPECTIONS, \n              EXAMINATIONS, AND INVESTIGATIONS.\n\n    For the purpose of increasing the capacity of the Food and Drug \nAdministration to conduct inspections, examinations, and investigations \nunder the Federal Food, Drug, and Cosmetic Act with respect to \nviolations described in paragraphs (3) and (4) of section 303(a) of \nsuch Act, there is authorized to be appropriated $60,000,000 for each \nof the fiscal years 2015 through 2018, in addition to other \nauthorizations of appropriations that are available for such purpose.\n\nSEC. 5. PUBLIC EDUCATION REGARDING COUNTERFEIT DRUGS.\n\n    (a) In General.--The Secretary of Health and Human Services shall \ncarry out a program to educate the public and health care professionals \non counterfeit drugs, including techniques to identify drugs as \ncounterfeit.\n    (b) Authorization of Appropriations.--For the purpose of carrying \nout subsection (a), there is authorized to be appropriated $5,000,000 \nfor each of the fiscal years 2015 through 2018, in addition to other \nauthorizations of appropriations that are available for such purpose.\n\nSEC. 6. RECALL AUTHORITY REGARDING DRUGS.\n\n    Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 351 et seq.) is amended by inserting after section 506F \nthe following section:\n\n``SEC. 506G. RECALL AUTHORITY.\n\n    ``(a) Order To Cease Distribution of Drug; Notification of Health \nProfessionals.--\n            ``(1) In general.--If the Secretary finds that a drug \n        intended for human use may constitute a threat to the public \n        health, the Secretary shall issue an order requiring the \n        appropriate person (including the manufacturers, importers, \n        distributors, or retailers of the drug)--\n                    ``(A) to immediately cease distribution of the \n                drug; and\n                    ``(B) to immediately notify health professionals of \n                the order and to instruct such professionals to cease \n                administering, distributing, selling, or prescribing \n                the drug.\n            ``(2) Informal hearing.--An order under paragraph (1) shall \n        provide the person subject to the order with an opportunity for \n        an informal hearing, to be held not later than 10 days after \n        the date of the issuance of the order, on the actions required \n        by the order and on whether the order should be amended to \n        require a recall of the drug involved. If, after providing an \n        opportunity for such a hearing, the Secretary determines that \n        inadequate grounds exist to support the actions required by the \n        order, the Secretary shall vacate the order.\n    ``(b) Order To Recall Drug.--\n            ``(1) In general.--If, after providing an opportunity for \n        an informal hearing under subsection (a)(2), the Secretary \n        determines that the order should be amended to include a recall \n        of the drug with respect to which the order was issued, the \n        Secretary shall, except as provided in paragraphs (2) and (3), \n        amend the order to require a recall. The Secretary shall \n        specify a timetable in which the drug recall will occur and \n        shall require periodic reports to the Secretary describing the \n        progress of the recall.\n            ``(2) Certain actions.--An amended order under paragraph \n        (1)--\n                    ``(A) shall not require recall of a drug from \n                individuals; and\n                    ``(B) shall provide for notice to individuals \n                subject to the risks associated with the use of the \n                drug.\n            ``(3) Assistance of health professionals.--In providing the \n        notice required by paragraph (2)(B), the Secretary may use the \n        assistance of health professionals who administered the drug \n        involved to individuals or prescribed the drug for individuals. \n        If a significant number of such individuals cannot be \n        identified, the Secretary shall notify such individuals \n        pursuant to section 705(b).''.\n\nSEC. 7. AUTHORITY TO ISSUE SUBPOENAS WITH RESPECT TO PREVENTING THREATS \n              TO THE PUBLIC HEALTH.\n\n    Section 303 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n333(a)) is amended by adding at the end the following subsection:\n    ``(h) The Secretary and the Attorney General shall develop and \nimplement a procedure through which the Chief Counsel in the Food and \nDrug Administration is authorized to issue subpoenas regarding \ninvestigations under this Act of acts or omissions that may constitute \na threat to the public health, including investigations of alleged \nviolations to which paragraph (3) or (4) of subsection (a) apply and \nalleged violations with respect to which the Secretary is considering \nthe use of authorities under section 304.''."
}